Skip to content

Microneedling Plus the Universal Peel For Acne Scarring

Efficacy of Combination Therapy With Microneedling and the Universal Peel For Acne Scarring in Skin Types III-VI

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02174393
Enrollment
15
Registered
2014-06-25
Start date
2014-07-31
Completion date
2015-12-31
Last updated
2016-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne Scarring

Brief summary

Acne is a prevalent disorder mostly witnessed in adolescents, but can be seen in adults. Early treatment is imperative to reduce acne scarring which can appear with atrophic lesions, and depending on the skin type, significant erythema (redness) or post-inflammatory hyperpigmentation. A multi-modality approach to treatment is necessary when dealing with the aforementioned types of lesions. Pharmacologic management is essential, but safe procedural therapies are also necessary specifically with darker skinned individuals. Percutaneous collagen induction therapy (PCIT) is a non-invasive treatment achieved by using a micro-needling device, which is safe and effective in causing micro-wounds into the dermis thereby initiating wound healing followed by collagen production. This is an ideal treatment for acne scarring, re-texturizing of the skin, and hyperpigmentation for all skin types . Currently there are very few studies evaluating the safety and efficacy of microneedling and chemical peels in skin types III-VI. The aim of this study is to evaluate the effects of the combination of microneedling and chemical peel for the treatment of acne scars in skin types III-VI.

Interventions

DRUGUniversal Peel

Universal Peel: is a chemical peel consisting of a mild acid solution. (5 min Peel and 5 min Retinol)

PROCEDUREMicroneedling

Microneedling: is a device for all skin types that creates micro injuries in the dermis (layer of the skin underneath the outermost layer) in an attempt to trigger new collagen (natural component of skin tissue) production for smoother, firmer and younger-looking skin. For this protocol, the needle depth will be increased over the 3 sessions: Forehead: 0.75 mm, 0.85 mm, 1.0 mm. Cheeks/Chin: 1.0 mm, 1.5 mm, 2.0 mm. Each Session: Microneedling procedure on Day 1, followed by skin care regimen

DRUGPost-Microneedling Skin Care

On Day 1 (after Microneedling procedure): * Gentle Antioxidant Soothing Cleanser daily * Soothing Recovery Ointment and Sheer Physical Sunscreen On Day 2-7: * AM: Physical sheer sunscreen and recovery ointment * PM: Retinol/Vitamin C in the evening and soothing recovery ointment On Day 7: * AM: BD Hydrating Day/Night Cream * PM: Retinol and Vitamin C and the BD Hydrating Day/Night Cream (if necessary)

DRUGPost-Universal Peel Skin Care

* Gentle Antioxidant Soothing Cleanser daily * Physical Sunscreen daily * Soothing recovery ointment fortified with silver only when peeling occurs * After completely peeling, vitamin c product in the morning and the retinol in the evening

Sponsors

Topix Pharmaceuticals
CollaboratorUNKNOWN
Eclipse Aesthetics
CollaboratorUNKNOWN
Englewood Hospital and Medical Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Subject \> 18 and \< 60 years of age. * Subject has skin type III, IV, V, or VI as defined by the Fitzpatrick Classification Scale. * Subject has acne scarring as defined by the Goodman and Baron Grading System.

Exclusion criteria

* Subject currently has moderate to severe acne on the face. * Subject has an active infection. * Subject is pregnant or lactating. * Subject has a history of a bleeding disorder. * Subject is taking an anti-coagulant. * Subject has a history of keloidal tendency. * Subject has received ablative or non-ablative laser treatments in the previous 6 months. * Subject has taken Accutane within the previous 3 months.

Design outcomes

Primary

MeasureTime frameDescription
Improvement in the appearance of acne scarring as measured by The Goodman and Baron Grading Scale.6 monthsThe scale will be completed at every office visit over the 6 month study (Baseline, Weeks 1, 3, 5, 7, 9, 11, and 17).
Improvement in the appearance of acne scarring as measured by the 4 Point Scar Scale.6 MonthsThe scale will be completed at each office visit during the 6 month study (Baseline, Weeks 1, 3, 5, 7, 9, 11, and 17).
Improvement in the appearance of acne scarring as measured by the Global Assessment.6 monthsThe Global Assessment of Improvement will be completed at Week 17.

Secondary

MeasureTime frameDescription
Improvement in the appearance of acne scarring as subjectively measured through digital pictures.6 monthsPictures of the subject will be taken by the Principal Investigator at every office visit during the 6 month study (Baseline, Weeks 1, 3, 5, 7, 9, 11, and 17).
Patient-reported improvement in the appearance of acne scarring as measured by the Cardiff Index.6 monthsThe Cardiff Index will be completed at Baseline and Week 17.
Patient reported improvement in appearance of acne scarring a measured by pre and post-treatment questionnaires.6 monthsSubject will complete a pre-treatment questionnaire at Baseline and post-treatment questionnaires at Weeks 7 and 17.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026